Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5466]

Launch of trial of 'Master Switch' drug to treat several cancer types

Launch of trial of 'Master Switch' drug to treat several cancer types

Precise targeting improves drug for leukaemias and lymphomas

Precise targeting improves drug for leukaemias and lymphomas

Ovarian cancer stem cell study puts targeted therapies within reach

Ovarian cancer stem cell study puts targeted therapies within reach

Researchers find new molecule to target in pancreatic cancer treatment

Researchers find new molecule to target in pancreatic cancer treatment

Scientists use 'virtual experiments' to uncover missing cancer targets

Scientists use 'virtual experiments' to uncover missing cancer targets

ASH 2012: Histone deacetylases targeted as new strategy against graft versus host disease

ASH 2012: Histone deacetylases targeted as new strategy against graft versus host disease

$ASH 2012: Pomalidomide with low-dose dexamethasone demonstrates significant progression free survival and overall survival advantage for relapsed/refractory multiple myeloma$

ASH 2012: Pomalidomide with low-dose dexamethasone demonstrates significant progression free survival and overall...

ASH 2012: New proteasome inhibitor MLN9708 increases efficacy of treatment for multiple myeloma

ASH 2012: New proteasome inhibitor MLN9708 increases efficacy of treatment for multiple myeloma

ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

ASH 2012: Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant

ASH 2012: Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant

More from ecancer